Compare Stocks: CNTX, INO, FHTX, and GNLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.30 +1.7%	$0.41	$0.30 ▼ $3.62	$27.95M	1.71	1.09 million shs	576,204 shs
FHTX Foghorn Therapeutics	$2.00 +0.5%	$4.82	$1.79 ▼ $7.61	$118.77M	3.01	1.36 million shs	646,749 shs
GNLX Genelux	$2.56 +2.4%	$2.59	$2.29 ▼ $8.53	$115.83M	0.59	235,615 shs	154,650 shs
INO Inovio Pharmaceuticals	$1.15 +5.5%	$1.14	$0.56 ▼ $2.72	$118.91M	1.61	2.76 million shs	2.89 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	0.00%	-1.78%	-16.98%	-53.41%	-73.32%
FHTX Foghorn Therapeutics	0.00%	-0.99%	-55.46%	-66.39%	-55.56%
GNLX Genelux	0.00%	0.00%	+3.23%	-15.51%	-46.11%
INO Inovio Pharmaceuticals	0.00%	-0.86%	-10.16%	-2.54%	-55.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.30 +1.7%	$0.41	$0.30 ▼ $3.62	$27.95M	1.71	1.09 million shs	576,204 shs
FHTX Foghorn Therapeutics	$2.00 +0.5%	$4.82	$1.79 ▼ $7.61	$118.77M	3.01	1.36 million shs	646,749 shs
GNLX Genelux	$2.56 +2.4%	$2.59	$2.29 ▼ $8.53	$115.83M	0.59	235,615 shs	154,650 shs
INO Inovio Pharmaceuticals	$1.15 +5.5%	$1.14	$0.56 ▼ $2.72	$118.91M	1.61	2.76 million shs	2.89 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	0.00%	-1.78%	-16.98%	-53.41%	-73.32%
FHTX Foghorn Therapeutics	0.00%	-0.99%	-55.46%	-66.39%	-55.56%
GNLX Genelux	0.00%	0.00%	+3.23%	-15.51%	-46.11%
INO Inovio Pharmaceuticals	0.00%	-0.86%	-10.16%	-2.54%	-55.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	2.67	Moderate Buy	$6.17	1,927.18% Upside
FHTX Foghorn Therapeutics	2.30	Hold	$6.67	233.33% Upside
GNLX Genelux	2.80	Moderate Buy	$18.00	603.13% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	175.36% Upside

Current Analyst Ratings Breakdown

Latest CNTX, INO, FHTX, and GNLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	FHTX Foghorn Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $5.00
10/2/2026	FHTX Foghorn Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $2.00
10/2/2026	FHTX Foghorn Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $5.00
10/2/2026	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $5.00
10/1/2026	FHTX Foghorn Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
10/1/2026	FHTX Foghorn Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
10/1/2026	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
10/1/2026	FHTX Foghorn Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00
10/1/2026	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/17/2026	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/16/2026	GNLX Genelux	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
FHTX Foghorn Therapeutics	$30.91M	3.84	N/A	N/A	($1.92) per share	-1.04
GNLX Genelux	$10K	11,581.44	N/A	N/A	$0.30 per share	8.53
INO Inovio Pharmaceuticals	$60K	1,981.83	N/A	N/A	$0.36 per share	3.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	11/4/2026 (Estimated)
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	11/4/2026 (Estimated)
GNLX Genelux	-$32.15M	-$0.86	N/A	N/A	N/A	N/A	-205.85%	-138.79%	11/4/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)

Latest CNTX, INO, FHTX, and GNLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	CNTX Context Therapeutics	-$0.09	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	FHTX Foghorn Therapeutics	-$0.23	N/A	N/A	N/A	$6.39 million	N/A
11/4/2026	Q3 2026	GNLX Genelux	-$0.20	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	GNLX Genelux	-$0.1967	-$0.21	-$0.0133	-$0.21	N/A	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.07 million
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	5.81	5.81
FHTX Foghorn Therapeutics	N/A	3.36	3.36
GNLX Genelux	N/A	2.39	2.39
INO Inovio Pharmaceuticals	N/A	1.00	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
FHTX Foghorn Therapeutics	61.55%
GNLX Genelux	37.33%
INO Inovio Pharmaceuticals	26.79%

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	4.80%
FHTX Foghorn Therapeutics	9.02%
GNLX Genelux	7.50%
INO Inovio Pharmaceuticals	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	15	91.88 million	87.47 million	Not Optionable
FHTX Foghorn Therapeutics	106	59.38 million	54.03 million	Optionable
GNLX Genelux	26	45.24 million	41.85 million	Not Optionable
INO Inovio Pharmaceuticals	112	103.40 million	101.64 million	Optionable

CNTX, INO, FHTX, and GNLX Headlines

Recent News About These Companies

FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer

October 8 at 1:02 PM | finance.yahoo.com

Inovio Pharmaceuticals stock gained 1.77 percent before FDA date

October 8 at 1:08 AM | ad-hoc-news.deA

Inovio Updates Bylaws with New Exclusive-Forum Provision

October 6, 2026 | tipranks.com

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

October 5, 2026 | finance.yahoo.com

Inovio Pharmaceuticals stock fell 4.13 percent before FDA decision

October 4, 2026 | ad-hoc-news.deA

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

October 2, 2026 | americanbankingnews.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Stock Has Consensus Target Price of $3.17 According to Analysts

October 2, 2026 | marketbeat.com

Inovio Pharmaceuticals stock approaches its October FDA test

September 30, 2026 | ad-hoc-news.deA

Inovio Pharmaceuticals (NASDAQ:INO) Share Price Breaks Above 200-Day Moving Average - Should You Sell?

September 29, 2026 | marketbeat.com

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

September 24, 2026 | finance.yahoo.com

Inovio Pharmaceuticals stock trades lower as FDA date nears

September 23, 2026 | ad-hoc-news.deA

Inovio Pharmaceuticals stock gains as price crosses 200-day moving average

September 19, 2026 | ad-hoc-news.deA

Inovio Pharmaceuticals (NASDAQ:INO) Share Price Crosses Above 200 Day Moving Average - Here's Why

September 19, 2026 | marketbeat.com

Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view

September 18, 2026 | ad-hoc-news.deA

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

September 14, 2026 | finance.yahoo.com

Bet on 4 Top-Ranked Stocks With Rising P/E

September 14, 2026 | zacks.com

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

September 11, 2026 | seekingalpha.com

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

September 11, 2026 | marketbeat.com

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

September 10, 2026 | finance.yahoo.com

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 9, 2026 | seekingalpha.com

Bet on 5 Top-Ranked Stocks With Rising P/E

September 3, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CNTX, INO, FHTX, and GNLX Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.30 +0.01 (+1.74%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.30 -0.01 (-1.71%)

As of 10/9/2026 07:45 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Foghorn Therapeutics NASDAQ:FHTX

$2.00 +0.01 (+0.50%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.00 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Genelux NASDAQ:GNLX

$2.56 +0.06 (+2.40%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.56 +0.00 (+0.20%)

As of 10/9/2026 07:30 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Inovio Pharmaceuticals NASDAQ:INO

$1.15 +0.06 (+5.50%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.14 -0.01 (-0.87%)

As of 10/9/2026 07:55 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTX, INO, FHTX, and GNLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTX, INO, FHTX, and GNLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTX, INO, FHTX, and GNLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CNTX, INO, FHTX, and GNLX Company Descriptions

Context Therapeutics NASDAQ:CNTX

Foghorn Therapeutics NASDAQ:FHTX

Genelux NASDAQ:GNLX

Inovio Pharmaceuticals NASDAQ:INO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTX, INO, FHTX, and GNLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTX, INO, FHTX, and GNLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTX, INO, FHTX, and GNLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CNTX, INO, FHTX, and GNLX Company Descriptions

Context Therapeutics NASDAQ:CNTX

Foghorn Therapeutics NASDAQ:FHTX

Genelux NASDAQ:GNLX

Inovio Pharmaceuticals NASDAQ:INO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools